Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL).
McInnes IB, Asahina A, Coates LC, Landewé R, Merola JF, Ritchlin CT, Tanaka Y, Gossec L, Gottlieb AB, Warren RB, Ink B, Assudani D, Bajracharya R, Shende V, Coarse J, Mease PJ. McInnes IB, et al. Among authors: ink b. Lancet. 2023 Jan 7;401(10370):25-37. doi: 10.1016/S0140-6736(22)02302-9. Epub 2022 Dec 6. Lancet. 2023. PMID: 36493791 Free article. Clinical Trial.
Safety and Efficacy of Bimekizumab in Patients With Active Psoriatic Arthritis: Three-Year Results From a Phase IIb Randomized Controlled Trial and Its Open-Label Extension Study.
Coates LC, McInnes IB, Merola JF, Warren RB, Kavanaugh A, Gottlieb AB, Gossec L, Assudani D, Bajracharya R, Coarse J, Ink B, Ritchlin CT. Coates LC, et al. Among authors: ink b. Arthritis Rheumatol. 2022 Dec;74(12):1959-1970. doi: 10.1002/art.42280. Epub 2022 Nov 18. Arthritis Rheumatol. 2022. PMID: 35829656 Free PMC article. Clinical Trial.
Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE).
Merola JF, Landewé R, McInnes IB, Mease PJ, Ritchlin CT, Tanaka Y, Asahina A, Behrens F, Gladman DD, Gossec L, Gottlieb AB, Thaçi D, Warren RB, Ink B, Assudani D, Bajracharya R, Shende V, Coarse J, Coates LC. Merola JF, et al. Among authors: ink b. Lancet. 2023 Jan 7;401(10370):38-48. doi: 10.1016/S0140-6736(22)02303-0. Epub 2022 Dec 6. Lancet. 2023. PMID: 36495881 Free article. Clinical Trial.
Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study.
Ritchlin CT, Coates LC, McInnes IB, Mease PJ, Merola JF, Tanaka Y, Asahina A, Gossec L, Gottlieb AB, Warren RB, Ink B, Bajracharya R, Shende V, Coarse J, Landewé RB. Ritchlin CT, et al. Among authors: ink b. Ann Rheum Dis. 2023 Nov;82(11):1404-1414. doi: 10.1136/ard-2023-224431. Epub 2023 Sep 11. Ann Rheum Dis. 2023. PMID: 37696588 Free PMC article. Clinical Trial.
Validity and score interpretation of the 12-item Psoriatic Arthritis Impact of Disease: an analysis of pooled data from two phase 3 trials of bimekizumab in patients with psoriatic arthritis.
Gossec L, Orbai AM, Coates LC, Gladman DD, Ogdie A, Pelligra CG, Ciaravino V, Ink B, Taieb V, Lambert J, de Wit M. Gossec L, et al. Among authors: ink b. RMD Open. 2024 Jan 31;10(1):e003548. doi: 10.1136/rmdopen-2023-003548. RMD Open. 2024. PMID: 38296802 Free PMC article. Clinical Trial.
Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL.
Coates LC, Landewé R, McInnes IB, Mease PJ, Ritchlin CT, Tanaka Y, Asahina A, Behrens F, Gladman DD, Gossec L, Orbai AM, Gottlieb AB, Warren RB, Ink B, Bajracharya R, Shende V, Coarse J, Merola JF. Coates LC, et al. Among authors: ink b. RMD Open. 2024 Feb 22;10(1):e003855. doi: 10.1136/rmdopen-2023-003855. RMD Open. 2024. PMID: 38388171 Free PMC article. Clinical Trial.
21 results